Knockdown of PLAGL2 inhibits oral squamous cell carcinoma cell growth and cisplatin resistance via ZEB1/PD-L1 pathway

被引:0
|
作者
Zhang, Changqing [1 ]
Ye, Fei [1 ]
机构
[1] Wuhan Hankou Hosp, Dept Stomatol, Wuhan 430012, Hubei, Peoples R China
关键词
PLAGL2; Oral squamous cell carcinoma (OSCC); Cell proliferation; Metastasis; Tumor immunity; ZEB1; Programmed cell death ligand 1; EPITHELIAL-MESENCHYMAL TRANSITION; EXPRESSION;
D O I
10.4314/tjpr.v22i1.7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To investigate the effects of pleomorphic adenoma gene like-2 (PLAGL2) on oral squamous cell carcinoma (OSCC). Methods: The effects of PLAGL2 on OSCC (CAL-27 and HSC-3) were conducted with loss-and gain -functional assays. Cell proliferation was determined by Cell Counting Kit-8 (CCK8) and colony formation assays. Cell metastasis was assessed by Transwell and wound healing assays. Cell apoptosis of cisplatin-resistant OSCC was evaluated by flow cytometry. Results: PLAGL2 expression was significantly elevated in OSCC (p < 0.001), while silencing of PLAGL2 significantly reduced cell proliferation and metastasis of OSCC (p < 0.001). However, overexpression of PLAGL2 promoted OSCC progression through increase in cell proliferation, invasion, and migration. Knockdown of PLAGL2 promoted cell apoptosis of-resistant OSCC, but significantly downregulated protein expression of programmed cell death ligand 1(PD-L1) and zinc finger E-box -binding homeobox 1 (ZEB1) in OSCC (p < 0.01). Moreover, loss of ZEB1 attenuated the PLAGL2 overexpression-induced increase in ZEB1 and PD-L1. Loss of PLAGL2 also reduced in vivo tumor growth of OSCC via regulation of cluster of differentiation 4 protein (CD4) and CD8. Conclusion: Knockdown of PLAGL2 exerts anti-tumor effects, improves cisplatin resistance, and enhances anti-tumor immunity in OSCC through suppression of ZEB1/PD-L1 pathway. Thus, PLAGL2 might be a potential therapeutic target for the treatment of OSCC.
引用
收藏
页码:45 / 51
页数:7
相关论文
共 50 条
  • [11] Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma
    Blatt, Sebastian
    Krueger, Maximilian
    Rump, Constantin
    Zimmer, Stefanie
    Sagheb, Keyvan
    Kuenzel, Julian
    PLOS ONE, 2022, 17 (05):
  • [12] Knockdown of PD-L1 in Murine Renal Cell Carcinoma Inhibits Tumor Growth and Enhances the Antitumor effect of Sunitinib
    Hara, Takuto
    Terakawa, Tomoaki
    CANCER SCIENCE, 2018, 109 : 983 - 983
  • [13] Correlation of PD-1 and PD-L1 expression in oral leukoplakia and oral squamous cell carcinoma: an immunohistochemical study
    Greeshma, L. R.
    Joseph, Anna P.
    Sivakumar, T. T.
    Pillai, Varun Raghavan
    Vijayakumar, Gopikrishnan
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [14] Correlation of PD-1 and PD-L1 expression in oral leukoplakia and oral squamous cell carcinoma: an immunohistochemical study
    L. R. Greeshma
    Anna P. Joseph
    T. T. Sivakumar
    Varun Raghavan Pillai
    Gopikrishnan Vijayakumar
    Scientific Reports, 13 (1)
  • [15] Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study
    Troeltzsch, Matthias
    Woodlock, Timothy
    Pianka, Alix
    Otto, Sven
    Troeltzsch, Markus
    Ehrenfeld, Michael
    Knoesel, Thomas
    JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2017, 75 (05) : 969 - 977
  • [16] Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors
    Gao, Antian
    Pan, Xiao
    Yang, Xudong
    Lin, Zitong
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1132 - 1138
  • [17] PD-L1 regulation by SDH5 via β-catenin/ZEB1 signaling
    Tuo, Zhan
    Zong, Yan
    Li, Jie
    Xiao, Guangqin
    Zhang, Furong
    Li, Guiling
    Wang, Sihua
    Lv, Yi
    Xia, Jiahong
    Liu, Jun
    ONCOIMMUNOLOGY, 2019, 8 (12):
  • [18] Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors
    Antian Gao
    Xiao Pan
    Xudong Yang
    Zitong Lin
    Investigational New Drugs, 2021, 39 : 1132 - 1138
  • [19] Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
    Kammerer-Jacquet, Solene-Florence
    Deleuze, Antoine
    Saout, Judikael
    Mathieu, Romain
    Laguerre, Brigitte
    Verhoest, Gregory
    Dugay, Frederic
    Belaud-Rotureau, Marc-Antoine
    Bensalah, Karim
    Rioux-Leclercq, Nathalie
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (07)
  • [20] Upregulation of PD-L1 expression by cisplatin in esophageal squamous cell carcinoma cells is independent of interferon/JAK/STAT pathway
    Huang, Ta-Chen
    Lin, Kuan-Ling
    Cheng, Ann-Lii
    Hsu, Chih-Hung
    CANCER RESEARCH, 2016, 76